Protalix
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Protalix sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Protalix: 5 sponsored US clinical trials, 1 recruiting.
Protalix sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fabry Disease, with 1 trials.
Upper-quartile sponsor footprint
Protalix sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
NCT07280156
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
NCT03180840
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
NCT02795676
Extension Study of PRX-102 for up to 60 Months
NCT01981720
Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients
NCT01678898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Protalix pipeline
1 recruiting of 5 indexed (20% open); 4 completed (80%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Fabry Disease (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Protalix: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Protalix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Protalix page
5 registered trials is a research-attention snapshot, not an endorsement of Protalix or any single study.
- 1 of Protalix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Fabry Disease is the condition Protalix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fabry Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Protalix pipeline card: 5 registered trials from official public datasets.Report a data error.